Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
Clinuvel Pharmaceuticals Ltd
Mallinckrodt Plc
Mitsubishi Tabe Pharma Corp
Palatin Technologies Inc
Syct Pharma AB
Viewpoint Molecular Targeting LLC
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
afamelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
History of Events
corticotropin - Drug Profile
Product Description
Mechanism Of Action
History of Events
CUV-9900 - Drug Profile
Product Description
Mechanism Of Action
History of Events
dersimelagon phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Next Generation of Compounds - Drug Profile
Product Description
Mechanism Of Action
Parvysmelanotide - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-8177 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-8331 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-9643 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PL-9654 - Drug Profile
Product Description
Mechanism Of Action
History of Events
VMT-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
Featured News & Press Releases
Jun 29, 2022: Syct Pharma recieves pre-IND response from the US FDA
Jun 22, 2022: Syct Pharma submits CTA for clinical phase 2b study in RA
May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual Intertiol Conference
May 10, 2022: Clinuvel progresses vitiligo study
May 09, 2022: CLINUVEL progresses vitiligo treatment program
May 04, 2022: CLINUVEL Pharmaceuticals : Positive fil results in stroke
May 04, 2022: Syct Pharma completes clinical pharmacokinetic test of AP1189 tablet
May 02, 2022: Palatin to present on PL9643 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
May 02, 2022: Palatin to present on PL-9654 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
May 02, 2022: Palatin to present on PL8177 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
Apr 21, 2022: Palatin to present at Eyecelerator American Society of Cataract and Refractive Surgery (ASCRS) 2022
Mar 15, 2022: Afamelanotide in stroke (AIS) - Positive prelimiry results
Mar 03, 2022: Palatin hosting key opinion leader webir on dry eye disease
Feb 14, 2022: CLINUVEL expands D repair program with 2nd D repair study
Jan 22, 2022: SCENESSE continued in Germany
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
Pipeline by Mallinckrodt Plc, 2022
Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Pipeline by Palatin Technologies Inc, 2022
Pipeline by SynAct Pharma AB, 2022
Pipeline by Viewpoint Molecular Targeting LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022